drugset / Trial / NCT00635557
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.
Timeline
- Start
- 2008-03
- Primary completion
- 2010-10
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Verubulin | Small molecule | 2.1 mg/m2 | Intravenous |
| Subject | Verubulin | Small molecule | 2.7 mg/m2 | Intravenous |
| Subject | Verubulin | Small molecule | 3.3 mg/m2 | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |